[HTML][HTML] The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of …
A Nicholson, J Mahon, A Boland, S Beale… - Health Technology …, 2015 - europepmc.org
A Nicholson, J Mahon, A Boland, S Beale, K Dwan, N Fleeman, J Hockenhull, Y Dundar
Health Technology Assessment (Winchester, England), 2015•europepmc.orgBackground There is no single definitive test to identify prostate cancer in men. Biopsies are
commonly used to obtain samples of prostate tissue for histopathological examination.
However, this approach frequently misses cases of cancer, meaning that repeat biopsies
may be necessary to obtain a diagnosis. The PROGENSA (®) prostate cancer antigen 3
(PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index
(phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test …
commonly used to obtain samples of prostate tissue for histopathological examination.
However, this approach frequently misses cases of cancer, meaning that repeat biopsies
may be necessary to obtain a diagnosis. The PROGENSA (®) prostate cancer antigen 3
(PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index
(phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test …
Background
There is no single definitive test to identify prostate cancer in men. Biopsies are commonly used to obtain samples of prostate tissue for histopathological examination. However, this approach frequently misses cases of cancer, meaning that repeat biopsies may be necessary to obtain a diagnosis. The PROGENSA (®) prostate cancer antigen 3 (PCA3) assay (Hologic Gen-Probe, Marlborough, MA, USA) and the Prostate Health Index (phi; Beckman Coulter Inc., Brea, CA, USA) are two new tests (a urine test and a blood test, respectively) that are designed to be used to help clinicians decide whether or not to recommend a repeat biopsy.
Objective
To evaluate the clinical effectiveness and cost-effectiveness of the PCA3 assay and the phi in the diagnosis of prostate cancer.
europepmc.org
以上显示的是最相近的搜索结果。 查看全部搜索结果